CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

psilocybin

Small moleculeexperimental

Psilocybin, also known as 4-phosphoryloxy-N,N-dimethyltryptamine (4-PO-DMT), is a naturally occurring tryptamine alkaloid and investigational drug found in more than 200 species of mushrooms, with hallucinogenic and serotonergic effects. Effects include euphoria, changes in perception, a distorted sense of time, and perceived spiritual experiences. It can also cause adverse reactions such as nausea and panic attacks. Its effects depend on set and setting and one's expectations. — Wikipedia

Clinical trial activity

245 trials · 159 clinical orgs · 0 marketing orgs

Phase 1
105
Phase 2
142
Phase 3
9
Phase 4
0

Earliest trial started Apr 1, 2004 (NCT00302744)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12
Mol. weight
284.25 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Prodrug

Sources

Also known as

  • cy-39
  • cy-39
  • psilocybin
  • psilocybin
  • psilocybin
  • psilocybine
  • psilocybine
  • psilocybine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07306364Phase 2Jun 30, 2026National Center for Complementary and Integrative Health (NCCIH), Yale University
NCT07226232Phase 3Jun 1, 2026Department of Veteran Affairs
NCT07227909Phase 2May 4, 2026University of Texas at Houston, Usona Institute
NCT07296094Phase 2May 1, 2026Harvard University
NCT07211438Phase 2Apr 1, 2026University of Toronto
NCT06992999Phase 1/Phase 2 (Phase 2)Jan 31, 2026University of Arizona
NCT07296328Phase 2Jan 15, 2026New York University
NCT07281352Phase 1/Phase 2 (Phase 2)Jan 5, 2026National Center for Complementary and Integrative Health (NCCIH), University of California, Los Angeles
NCT06988319Phase 1Jan 1, 2026Oregon Health and Science University, Portland Psychotherapy Clinic, Research, and Training Center
NCT07251491Phase 1/Phase 2 (Phase 2)Jan 1, 2026Department of Defense, Department of Veteran Affairs, Usona Institute
NCT07053917Phase 1Dec 31, 2025Johns Hopkins University, University of California, Berkeley, Usona Institute
NCT06902974Phase 2Dec 31, 2025Sunstone Medical
NCT07275970Phase 1Dec 31, 2025Scottsdale Healthcare
NCT07183748Phase 2Dec 1, 2025Ben Gurion University
NCT07079930Phase 1Nov 30, 2025Hebrew University
NCT07104916Phase 2Nov 30, 2025Ohio State University
NCT07216404Phase 2Nov 20, 2025Ohio State University
NCT06943573Phase 3Oct 31, 2025University of British Columbia
NCT07210112Phase 2Oct 8, 2025Centre Hospitalier St Anne
NCT07169747Phase 2Oct 1, 2025Region Skane
Showing 20 of 245 trials
Page 1 / 13

Organizations

Research & Development (159)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Johns Hopkins UniversityAcademic/Hospital313032007
Usona InstituteAcademic/Hospital18332017
COMPASS PathwaysFor profit14722018
University of TorontoAcademic/Hospital131322022
Heffter Research InstituteAcademic/Hospital12032004
Yale UniversityAcademic/Hospital121222016
University of California, San FranciscoAcademic/Hospital111022017
New York UniversityAcademic/Hospital9832009
University of WisconsinAcademic/Hospital8812014
University of BaselAcademic/Hospital7722018
Harvard UniversityAcademic/Hospital6522021
Steven & Alexandra Cohen Children's Medical Center, New YorkAcademic/Hospital6022022
University of British ColumbiaAcademic/Hospital6232022
University of California, Los AngelesAcademic/Hospital6422004
Imperial College LondonAcademic/Hospital5422018
University of CalgaryAcademic/Hospital5422023
University of CopenhagenAcademic/Hospital5422017
Filament Health Corp.Academic/Hospital4222022
National Institute on Drug Abuse (NIDA)Government4022017
TRYP TherapeuticsFor profit4322021
159 organizations
Page 1 / 8